Samuel Seoane Ruzo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6787398/publications.pdf

Version: 2024-02-01

34 papers	1,174 citations	430874 18 h-index	395702 33 g-index
35 all docs	35 docs citations	35 times ranked	2133 citing authors

#	Article	IF	Citations
1	Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors. Clinical Cancer Research, 2011, 17, 5546-5552.	7.0	247
2	P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene, 2011, 30, 1059-1071.	5.9	92
3	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene, 2014, 33, 148-156.	5.9	78
4	Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells. Oncotarget, 2014, 5, 10692-10708.	1.8	75
5	Anti-inflammatory effect of conditioned medium from human uterine cervical stem cells in uveitis. Experimental Eye Research, 2016, 149, 84-92.	2.6	67
6	Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis. Oncogene, 2018, 37, 1430-1444.	5.9	58
7	Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation. European Journal of Endocrinology, 2005, 153, 335-344.	3.7	46
8	Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells. Journal of the National Cancer Institute, 2010, 102, 1432-1446.	6.3	43
9	Carborane-based design of a potent vitamin D receptor agonist. Chemical Science, 2016, 7, 1033-1037.	7.4	43
10	Deregulation of the Pit-1 transcription factor in human breast cancer cells promotes tumor growth and metastasis. Journal of Clinical Investigation, 2010, 120, 4289-4302.	8.2	43
11	O-GlcNAcylated p53 in the liver modulates hepatic glucose production. Nature Communications, 2021, 12, 5068.	12.8	36
12	POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation. Oncogene, 2021, 40, 2725-2740.	5.9	32
13	Localization of a Negative Vitamin D Response Sequence in the Human Growth Hormone Gene. Biochemical and Biophysical Research Communications, 2002, 292, 250-255.	2.1	29
14	The Vitamin D Receptor Represses Transcription of the Pituitary Transcription Factor Pit-1 Gene without Involvement of the Retinoid X Receptor. Molecular Endocrinology, 2006, 20, 735-748.	3.7	27
15	POU1F1 transcription factor promotes breast cancer metastasis via recruitment and polarization of macrophages. Journal of Pathology, 2019, 249, 381-394.	4.5	26
16	Corneal regeneration by conditioned medium of human uterine cervical stem cells is mediated by TIMP-1 and TIMP-2. Experimental Eye Research, 2019, 180, 110-121.	2.6	25
17	Synthesis and Biological Evaluation of 1Î±,25-Dihydroxyvitamin D₃ Analogues with a Long Side Chain at C12 and Short C17 Side Chains. Journal of Medicinal Chemistry, 2012, 55, 8642-8656.	6.4	18
18	Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node. Oncogene, 2016, 35, 2756-2765.	5.9	18

#	Article	IF	Citations
19	Aromatic-Based Design of Highly Active and Noncalcemic Vitamin D Receptor Agonists. Journal of Medicinal Chemistry, 2018, 61, 4928-4937.	6.4	18
20	The Pit-1/Pou1f1 transcription factor regulates and correlates with prolactin expression in human breast cell lines and tumors. Endocrine-Related Cancer, 2010, 17, 73-85.	3.1	16
21	Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. Cellular Signalling, 2013, 25, 2281-2289.	3.6	16
22	Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of metalloproteinase (MMP)-13. Breast Cancer Research, 2014, 16, 505.	5.0	15
23	Administration of the optimized Î²-Lapachoneâ€“poloxamerâ€“cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 497-504.	4.3	14
24	Synthesis and Biological Activity of Two C-7 Methyl Analogues of Vitamin D. Journal of Organic Chemistry, 2015, 80, 165-173.	3.2	14
25	Cellular Expression Levels of the Vitamin D Receptor Are Critical to Its Transcriptional Regulation by the Pituitary Transcription Factor Pit-1. Molecular Endocrinology, 2007, 21, 1513-1525.	3.7	13
26	Synthesis, Structure, and Biological Activity of desâ€Side Chain Analogues of 1Î±,25â€Dihydroxyvitaminâ€…D₃ with Substituents at C18. ChemMedChem, 2011, 6, 788-793.	3.2	12
27	Biological evaluation of new vitamin D2 analogues. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 66-71.	2.5	12
28	Pit-1 inhibits BRCA1 and sensitizes human breast tumors to cisplatin and vitamin D treatment. Oncotarget, 2015, 6, 14456-14471.	1.8	12
29	Vitamin D, Pit-1, GH, and PRL: Possible Roles in Breast Cancer Development. Current Medicinal Chemistry, 2007, 14, 3051-3058.	2.4	10
30	Regulation of the prometastatic neuregulinâ€“<scp>MMP</scp>13 axis by <scp>SRC</scp> family kinases: therapeutic implications. Molecular Oncology, 2017, 11, 1788-1805.	4.6	7
31	Multisite phosphorylation of P-Rex1 by protein kinase C. Oncotarget, 2016, 7, 77937-77949.	1.8	7
32	Hepatic p63 regulates glucose metabolism by repressing SIRT1. Gut, 2023, 72, 472-483.	12.1	4
33	Synthesis of nonadeuterated 1Î±,25-dihydroxyvitamin D2. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 204-206.	2.5	1
34	26,26,26,27,27,27-Hexadeuterated-1,25-Dihydroxyvitamin D3 (1,25D-d6) As Adjuvant of Chemotherapy in Breast Cancer Cell Lines. Cancers, 2014, 6, 67-78.	3.7	0